This year’s World Antimicrobial Resistance Awareness Week is around the corner, and its mission – educating about the ongoing antimicrobial resistance crisis – is as important as ever. Here’s how Vax2Muc contributes to the fight against antibiotic resistance.

Vax2Muc partners met in Lisbon from 16 to 17 September to discuss project progress, brainstorm, and plan future activities.

Meet Vax2Muc scientist Cora Mibus from the Technical University in Munich. She is a doctoral student at TUM’s Institute of Medical Microbiology, Immunology and Hygiene and contributes to the Vax2Muc research as part of the network of international experts.

European Commission’s recent proposal on vaccine-preventable cancers included the EU-funded Vax2Muc project as an example of ongoing vaccine development to prevent gastric cancer.

Vax2Muc partners met in Copenhagen from March 13 to 14 to discuss vaccine research progress. With the vaccine design ending, the project's next stage will focus on trial vaccine production.

Eight months into the project, a group of Vax2Muc researchers from Helmholtz Centre for Infection Research (HZI), Statens Serum Institut (SSI), Technical University of Munich (TUM), and Trinity College Dublin (TCD) met in Munich to jointly explore technics and protocols for their future collaboration.

29 November 2023 - We are thrilled to announce the official launch of the Vax2Muc project website! 🚀

Munich, 25 August 2023 - The Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich (TUM) announced today the launch of Vax2Muc. Over the next 5 years, Vax2Muc will receive almost 8.5 million Euro from Horizon Europe to develop next generation vaccines against gastrointestinal mucosal pathogens.